Peptide Name
KPV
Updated April 2026
KPV Dosing Protocol
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: April 2026
Complete KPV dosing guide for KPV, a short anti-inflammatory peptide often discussed alongside BPC-157, covering KPV oral dosing and injectable protocols, KPV half-life context, reconstitution math, KPV gut barrier support rationale, and evidence limitations.
Half-life
Short; exact human PK not established
Dose range
200-500 mcg daily (oral or SubQ)
Status
Not FDA-approved
Clinical depth
Preclinical evidence only
Need to calculate reconstitution and dosing units? Use the peptide reconstitution calculator.
Quick Reference Dosing Card
Use Case
Research users commonly explore KPV for anti-inflammatory and gut-barrier support experiments.
Aliases
Lysine-Proline-Valine; Lys-Pro-Val; alpha-MSH (11-13); C-terminal tripeptide of alpha-MSH
Category / Class
Anti-Inflammatory / Melanocortin-Derived Peptide
Half-Life
Short; exact human plasma half-life is not established, but functional anti-inflammatory effects persist beyond circulation window
Dosing Frequency
Once daily SubQ or oral; some oral protocols are twice daily
Dose Range
200-500 mcg daily; some protocols use up to 1,000 mcg/day
Titration Schedule
SubQ: 200 mcg/day -> 300-400 mcg/day -> 400-500 mcg/day; oral: 200-500 mcg 1-2x daily
Common Vial Sizes
5mg, 10mg
Route of Administration
Subcutaneous, oral, topical, and nasal (less common)
Regulatory Status
Not FDA-approved. No completed human trials. Evidence base is preclinical and mechanistic.
Key Stat
Oral KPV significantly reduced gut inflammation in two standard animal models of colitis (DSS and TNBS) in the landmark 2008 Gastroenterology study that identified PepT1-mediated uptake.
Featured Suppliers
Peptide Partners
Direct product match with verified supplier link.
Orbitrex Peptides
Alternate product match for supplier comparison.
Need peptides? Start with a verified source.
These are PDP's two recommended suppliers, both USA-based, Finnrick-tested, and offering the PEPPAL discount code at checkout when eligible. For a side-by-side breakdown of our two recommended suppliers, read the full comparison.
Featured Suppliers
Our #1 Pick
Peptide Partners
Our #1 supplier
Same-day FedEx 2-Day Air, 59 Finnrick tests, multi-lab coverage, and the best per-mg value make Peptide Partners the recommended source for most buyers.
Single Vial?
Orbitrex Peptides
Need one vial?
Broader selection, single-vial orders, and Finnrick A-rated quality make Orbitrex a strong alternative for one-off purchases or harder-to-find compounds.
Affiliate disclosure: some outbound supplier links are affiliate links, and we may earn a commission at no extra cost to you. This supports our free tools and protocol database.
Need broader sourcing context before choosing a vendor? Compare all COA-verified suppliers in the PepPal supplier rankings.
What Is KPV?
KPV is a tiny anti-inflammatory peptide — just three amino acids long (lysine-proline-valine). It's a fragment of a larger natural hormone called alpha-MSH, which your body uses to regulate inflammation. Of all the fragments researchers have studied from alpha-MSH, KPV is the most explored for inflammation control.
What makes KPV unusual is that it can be taken orally. Most peptides break down in your digestive system before they can work, but KPV is small enough to be absorbed through specialized transporters (called PepT1) in your gut lining. This is why oral KPV protocols are common, especially for gut-focused applications — it can reach inflamed intestinal tissue directly.
Unlike some related compounds (such as melanotan), KPV does not cause skin tanning or pigmentation changes. It retains the anti-inflammatory properties of the parent hormone without the skin-darkening effects.
KPV is not FDA-approved for any indication and has no completed human efficacy trials. This page is educational research reference only.
How KPV Works: PepT1-Mediated NF-kB Inhibition and Barrier-Support Signaling
KPV works differently from most anti-inflammatory compounds. Instead of broadly suppressing your immune system (like steroids do), it targets a specific inflammation "switch" inside cells. Here's how each of its effects works:
Turning Down the Inflammation Switch (NF-kB Pathway)
Your cells have a master control pathway called NF-kB that activates inflammation — think of it as a switch that turns on swelling, redness, and immune responses. KPV is reported to reduce how long this switch stays "on" and how many inflammatory signals it produces. The result: lower inflammation without the broad immune suppression that comes with steroid-type approaches.
Getting Absorbed Where It's Needed Most (PepT1 Uptake)
One of KPV's most notable features is how it enters cells. Your gut lining has transporters called PepT1 that carry small peptides from your digestive tract into the cells that line your intestines. Research in colitis models found that inflamed gut tissue actually produces more of these transporters — meaning KPV may be preferentially absorbed in exactly the areas where inflammation is worst. This is also what makes oral dosing possible for KPV, unlike most injectable peptides.
Supporting the Gut Lining (Barrier and Mucosal Effects)
In preclinical studies, KPV has been associated with improved gut-lining integrity and faster mucosal healing. This is relevant for conditions involving "leaky gut" or inflammatory bowel disease (IBD), where the intestinal barrier is compromised and allows irritants to pass through.
Fighting Bacteria Too (Antimicrobial Activity)
Lab studies have also found that KPV has direct antimicrobial activity against certain bacteria and fungi. This makes it unusual — most anti-inflammatory peptides don't also kill pathogens. In situations where inflammation and infection overlap (common in gut conditions), this dual role is potentially valuable.
Together, these properties — targeted inflammation control, preferential uptake in inflamed tissue, barrier support, and antimicrobial activity — explain why KPV is one of the most discussed peptides for gut and skin inflammation protocols.
Tools for this Protocol
- dose to units converter for reconstitution and units.
- calculate injection units to lock in syringe draw volume.
KPV Dosing Protocol and Administration Schedule
Initiation (injectable)
Weeks 1-2
200 mcg/day SubQ
Low-start tolerance and response check.
Titration (injectable)
Weeks 3-4
300-400 mcg/day SubQ
Increase by about 100 mcg/week as tolerated.
Maintenance (injectable)
Weeks 5-12
400-500 mcg/day SubQ
Common anti-inflammatory maintenance window.
Oral standard
Weeks 1-8+
200-500 mcg once or twice daily
Preferred route for gut-focused workflows; take on empty stomach.
Oral intensive
Weeks 1-8+
500 mcg twice daily
Used in higher-burden inflammatory contexts.
Topical skin use
4-8+ weeks
Compounded topical, 1-2x daily
Applied to localized inflammatory skin targets.
Cycle standard
4-8 weeks on
Active dose
Typical 2-4 week off period.
Cycle extended
8-16 weeks on
Active dose
Longer protocols with periodic off windows.
Evidence Level Notice and Dosing Notes
Evidence level: No completed human dose-finding trials define optimal KPV dosing. Protocols are preclinical extrapolation and practitioner/community derived.
Route selection: Oral route is typically favored for gut-focused applications; SubQ route is favored for systemic delivery goals.
Empty-stomach guidance: Oral KPV is commonly taken on an empty stomach to reduce transporter competition from dietary peptides.
Pigmentation context: KPV does not have the receptor-binding sequence associated with tanning peptides and is generally modeled as non-pigmenting.
Missed dose: Resume next scheduled dose without doubling.
KPV Reconstitution Guide
Vial Size: 5 mg
BAC Water: 1 mL
Concentration: 5,000 mcg/mL
200 mcg: 0.04 mL (4 units)
300 mcg: 0.06 mL (6 units)
500 mcg: 0.10 mL (10 units)
Vial Size: 5 mg
BAC Water: 2 mL
Concentration: 2,500 mcg/mL
200 mcg: 0.08 mL (8 units)
300 mcg: 0.12 mL (12 units)
500 mcg: 0.20 mL (20 units)
Vial Size: 10 mg
BAC Water: 2 mL
Concentration: 5,000 mcg/mL
200 mcg: 0.04 mL (4 units)
300 mcg: 0.06 mL (6 units)
500 mcg: 0.10 mL (10 units)
Vial Size: 10 mg
BAC Water: 3 mL
Concentration: 3,333 mcg/mL
200 mcg: 0.06 mL (6 units)
300 mcg: 0.09 mL (9 units)
500 mcg: 0.15 mL (15 units)
Vial Size: 10 mg
BAC Water: 5 mL
Concentration: 2,000 mcg/mL
200 mcg: 0.10 mL (10 units)
300 mcg: 0.15 mL (15 units)
500 mcg: 0.25 mL (25 units)
Step-by-Step Reconstitution Instructions
- Wipe vial stopper with alcohol and allow to dry.
- Draw planned BAC water volume with a sterile syringe.
- Inject water against vial wall instead of directly onto powder.
- Allow gentle flow; avoid forced pressure.
- Roll vial gently for 30-60 seconds; do not shake.
- Inspect for clear, colorless solution before use.
- Label concentration/date and refrigerate at 2-8C. Use within 30 days.
KPV Side Effects and Safety
KPV appears to be well-tolerated based on animal studies and community experience, but no formal human safety trials have been completed — so long-term side effect data does not exist.
Evidence boundary: No completed human efficacy/safety trials currently define long-term dosing safety outcomes.
Common reports: Community-reported effects are usually mild: transient injection-site irritation, occasional mild headache, and occasional GI upset at higher oral doses.
Pigmentation effects: KPV is generally considered non-tanning and non-pigmenting in standard protocol use.
Immune profile:
How it affects your immune system: KPV works by dialing down specific inflammation pathways rather than suppressing your immune system broadly. This means it's not expected to make you more susceptible to infections the way steroids or other immunosuppressants might — though this has not been confirmed in human studies.
General cautions: Avoid use in pregnancy/breastfeeding and seek clinician oversight in complex inflammatory/infectious conditions.
KPV Research Evidence
KPV has not been tested in human clinical trials. All current evidence comes from animal studies and lab experiments. The table below summarizes the key published studies — note that "preclinical" means animal or cell-based research, not human testing.
Dalmasso et al. 2008
Preclinical + in vitro • Model-dependent
DSS/TNBS colitis models and epithelial cell systems
Oral KPV reduced colitis severity with PepT1-mediated uptake as a central mechanism finding.
Xiao et al. 2017
Preclinical • Model period
DSS colitis mouse model
Nanoparticle-delivered KPV improved targeting to inflamed colonic tissues and reduced inflammatory markers.
Kannengiesser et al. 2008
Preclinical + in vitro • Cell-assay based
Bronchial epithelial cell models
Dose-dependent suppression of TNF-driven inflammatory signaling and matrix-remodeling markers.
Catania et al. 2000
In vitro • Laboratory assay
S. aureus and C. albicans cultures
Reported direct antimicrobial activity, adding a dual anti-inflammatory/antimicrobial dimension.
Getting et al. 2006
Review • N/A
Multiple inflammation models
Summarized melanocortin-derived anti-inflammatory pharmacology and receptor-pathway distinctions relevant to KPV.
All KPV evidence to date is preclinical — meaning it comes from animal models and laboratory cell experiments, not human clinical trials. The gut-inflammation findings (especially the PepT1 transport discovery) are promising, but no completed human study has yet confirmed optimal dosing, how effective KPV actually is in people, or its long-term safety profile. This is an important limitation to keep in mind when evaluating KPV protocols.
Storage and Handling
Lyophilized (powder)
-20C (freezer)
Long-term (years)
Lyophilized (powder)
2-8C (refrigerator)
Months
Lyophilized (powder)
15-25C (room)
Weeks (shipping tolerance)
Reconstituted
2-8C (refrigerator)
Up to 30 days
Reconstituted
Do not freeze
N/A
Protect from light/moisture, avoid freeze-thaw cycling, and use bacteriostatic water for multi-dose workflows.
KPV vs BPC-157 vs alpha-MSH
KPV is often discussed alongside BPC-157 (a repair-focused peptide) and alpha-MSH (the full-length hormone KPV is derived from). The table below shows how they differ. The key distinction: KPV is focused on reducing inflammation, while BPC-157 is focused on repairing tissue.
Origin
KPV: C-terminal tripeptide fragment of alpha-MSH
BPC-157: Synthetic 15-AA gastric-protein fragment
alpha-MSH (full-length): Endogenous 13-AA melanocortin hormone
Primary Mechanism
KPV: Reduces inflammation by targeting the NF-kB pathway; absorbed via PepT1 transporters in the gut
BPC-157: Promotes blood vessel growth and tissue repair through protective signaling
alpha-MSH (full-length): Activates multiple melanocortin receptors, affecting pigmentation, inflammation, and appetite
Primary Use Model
KPV: Inflammation control and gut barrier support
BPC-157: Structural tissue repair
alpha-MSH (full-length): Pigmentation and melanocortin-system signaling
Oral Viability
KPV: Yes (PepT1-mediated)
BPC-157: Yes
alpha-MSH (full-length): Limited practical oral utility
Pigmentation Effects
KPV: No
BPC-157: No
alpha-MSH (full-length): Yes
Clinical Evidence
KPV: Preclinical only
BPC-157: Limited human + broad preclinical
alpha-MSH (full-length): Extensive hormonal research
KPV and BPC-157 are often paired in gut-focused protocols because KPV emphasizes inflammation control while BPC-157 emphasizes structural repair.
KPV should not be confused with melanotan compounds; pigmentation effects are not the target profile.
Dose units and route selection should be matched to protocol goals (gut-local, systemic, or skin-local models).
See the BPC-157 Protocol, TB-500 Protocol and GHK-Cu Protocol for compound-specific guides.
KPV Stacking Protocols
Before combining compounds, read the full stacking safety guide on PepPal.
Stack 1
KPV + BPC-157 (Gut Healing Stack)
KPV handles inflammatory signaling load while BPC-157 supports structural mucosal repair. Often run orally for gut-targeted workflows.
See the compound-specific See BPC-157 protocol for additional context.
View protocolStack 2
KPV + TB-500 (Systemic Inflammation + Repair)
Pairs inflammation control with deep tissue and migration support where multi-system recovery is needed.
See the compound-specific See TB-500 protocol for additional context.
View protocolStack 3
KPV + GHK-Cu (Anti-Inflammatory Skin Stack)
Combines inflammatory pathway control with collagen/remodeling support for skin-focused inflammatory contexts.
See the compound-specific See GHK-Cu protocol for additional context.
View protocolResearch Dispatch
Join the mailing list for new protocol and stack releases.
Get notified when new dosing references, stack breakdowns, and calculator-driven research pages go live. No multi-step signup, just the email field.
New protocol pages
Fresh stack breakdowns
Calculator-linked updates
Email signup
Short form. One field. Research updates only.
Frequently Asked Questions - KPV
Q1: What is the starting dose of KPV?
A common starting point is 200 mcg once daily (oral or SubQ), then titration toward 400-500 mcg/day based on response and tolerance.
Q2: What is KPV half-life?
KPV's exact half-life in humans hasn't been formally measured. As a very small peptide (just three amino acids), it likely breaks down quickly in the bloodstream. However, its anti-inflammatory effects inside cells appear to last longer than the peptide itself circulates — meaning it may keep working even after it's technically cleared from your blood.
Q3: What results can be expected from KPV?
Reported timelines often include early symptom shifts in 2-4 weeks, with broader anti-inflammatory trend changes over 6-12 weeks depending on context.
Q4: How do you reconstitute KPV?
Common setup is 10 mg with 2 mL (5,000 mcg/mL), where a 500 mcg dose equals 0.10 mL or 10 units on a U-100 syringe.
Q5: Is KPV FDA approved?
No. KPV is not FDA-approved for any indication and currently has no completed human clinical efficacy trials.
Q6: What are the most common side effects of KPV?
Community reports are usually mild and infrequent, such as temporary injection-site irritation, mild GI discomfort at higher oral doses, or occasional headache.
Q7: KPV vs BPC-157 for gut healing?
KPV and BPC-157 target different problems. KPV is focused on reducing inflammation — it calms down overactive immune signaling in the gut and other tissues. BPC-157 is focused on tissue repair — it helps damaged tissue heal by promoting blood vessel growth and protective cell signaling. They're commonly combined in gut-focused protocols because you often need both: calm the inflammation first (KPV), then support the repair process (BPC-157).
Q8: What vial sizes is KPV available in?
Most common lyophilized vial sizes are 5 mg and 10 mg.
Q9: How much bacteriostatic water for KPV?
10 mg with 2 mL or 3 mL are common choices. Lower concentration can improve draw precision for microgram-level dosing.
Q10: Can KPV be taken orally?
Yes. Oral KPV is a common protocol route, especially for gut-focused use, and is generally taken on an empty stomach.
Q11: How should reconstituted KPV be stored?
Store refrigerated at 2-8C, protect from light, and use within around 30 days. Do not freeze the reconstituted solution.
Q12: Does KPV cause skin tanning or pigmentation changes?
No. KPV is generally modeled as non-pigmenting and should not be confused with melanotan peptides.
Q13: Where can I calculate reconstitution and syringe units?
Use the PepPal calculator for exact dose-to-unit conversions.
Q14: Where can I compare peptide suppliers?
Browse the PepPal supplier directory for current supplier listings.
Sources & Research
- Dalmasso G, Charrier-Hisamuddin L, et al. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology, 2008 PubMed.
- Xiao B, Laroui H, et al. "Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis." Molecular Therapy, 2017 Link.
- Kannengiesser K, et al. "Kannengiesser et al. 2008 preclinical epithelial-cell KPV findings." Journal of Leukocyte Biology, 2008.
- Catania A, et al. "The peptide NDP-MSH induces phenotype changes in the heart that resemble those induced by melanocortin receptor agonists." Journal of Leukocyte Biology, 2000.
- Brzoska T, Luger TA, Maaser C, et al. "alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Annals of the Rheumatic Diseases, 2008 Link.
- Star RA, Rajora N, et al. "Evidence for autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone." PNAS, 1995.
- Getting SJ. "Targeting melanocortin receptors as potential novel therapeutics." Pharmacology and Therapeutics, 2006.
- Rajora N, Boccoli G, et al. "alpha-MSH modulates experimental inflammatory bowel disease." Peptides, 1997.
- Lee DJ, Kwon JY, et al. "The therapeutic potential of melanocortin peptides in inflammatory bowel disease." Nature Reviews Gastroenterology and Hepatology, 2018.
- Wang W, et al. "Melanocortin Regulation of Inflammation." Frontiers in Endocrinology, 2019 Link.
- Recent Advances in KPV Peptide Delivery (review article). Link.
- Wikipedia: Alpha-melanocyte-stimulating hormone. Link.
Related Protocols
Half-life: <30 min
BPC-157
Tissue Repair / Cytoprotective
View protocolHalf-life: <2 hours
TB-500
Tissue Repair / Actin Sequestration
View protocolHalf-life: ~30-60 min
GHK-Cu
Collagen Remodeling / Anti-Aging
View protocolStack Protocol
Wolverine Stack
Combined Tissue Repair
View protocolHalf-life: ~2 hours
Ipamorelin
GH Secretagogue
View protocolHalf-life: ~11 min
Sermorelin
GHRH Fragment
View protocolConvert this protocol into exact units and save it in Pep Pal with the Pep Pal calculator.
Disclaimer
The information on this page is for educational and research reference purposes only. KPV is not FDA-approved for any indication. No completed human clinical trials exist. No compounds discussed on this site are intended for human consumption. This is not medical advice.
This site contains affiliate links to vetted peptide suppliers. We may earn a commission at no extra cost to you. Our protocol content and editorial ratings are independent of affiliate relationships.